DHT.UN – FDA approves generics for a couple of pharmaceuticals in DHT.UN’s legacy portfolio
FDA approves two biosimilars for Eylea
On May 20, 2024, the FDA approved two biosimilars for eye treatment Eylea on which DHT.UN has two royalty streams. Both biosimilars are labeled as interchangeable, which implies that they can be substituted for the brand-name pharmaceutical at a pharmacy and without the need to consult the prescribing physician. A launch date for these biosimilars has not been announced yet and, to partially mitigate, Regeneron (the marketer of Eylea) will likely lean on a version of Eylea (Eylea HD approved in August 2023), which requires a less frequent treatment schedule vs. the biosimilars.
Eylea contributed ~4% of DHT.UN’s cash royalties in the LTM and the royalties expire in 2027.
(Source: Company disclosures, FDA)
FDA approves generic for Rydapt
On May 16, 2024, Lupin announced that it received approval from the FDA for a generic equivalent of Rydapt (midostaurin), a treatment for blood disorders including some types of blood cancers. A launch date has not been announced.
Rydapt contributed ~5% of DHT.UN’s cash royalties in the LTM and the U.S. royalty entitlement expires in Q1/2025.
(Source: Company disclosures)
Endri Leno, CFA
416-823-8125
https://www.linkedin.com/in/endri-leno-msc-mba-cfa/
Disclaimer & Disclosures
The views in these notes are the opinion of the writer, for informational purposes only and do not constitute financial, investment, or any other type of advice or any type of solicitation. All statements herein, other than statements of historical fact, are to be considered forward looking. Such forward-looking information and statements are based on my personal expectations, views, projections and/or publicly available information. Further, to the best of my knowledge, the information throughout these notes is current as of the date of transmission and based on sources believed to be accurate; although I make no representation as to the accuracy or completeness of the sources or these notes. All information in these notes is provided “as is” and I disclaim any duty to update any forward-looking expectations. All statements in these notes were independently developed by me and have not been endorsed, reviewed, influenced, etc. by anyone else. You may not disseminate or distribute any portion of these notes without my express written permission and they are intended to be read only in the jurisdictions where it is legally permissible to do so to conform local legal obligations. I expressly disclaim any liability for damages of any kind that may arise from or may be related to the view expressed in these notes.
The equities discussed are held by myself or members of my immediate family.